TY  - JOUR
AU  - Shahswar, Rabia
AU  - Beutel, Gernot
AU  - Gabdoulline, Razif
AU  - Schwarzer, Adrian
AU  - Kloos, Arnold
AU  - Koenecke, Christian
AU  - Stadler, Michael
AU  - Gohring, Gudrun
AU  - Behrens, Yvonne Lisa
AU  - Li, Zhixiong
AU  - Dallmann, Louisa-Kristin
AU  - Klement, Piroska
AU  - Albert, Catherin
AU  - Wichmann, Martin
AU  - Alwie, Yasmine
AU  - Benner, Axel
AU  - Saadati, Maral
AU  - Ganser, Arnold
AU  - Thol, Felicitas
AU  - Heuser, Michael
TI  - Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.
JO  - Haematologica
VL  - 109
IS  - 1
SN  - 0390-6078
CY  - Pavia
PB  - Ferrata Storti Foundation
M1  - DKFZ-2023-01475
SP  - 72-83
PY  - 2024
N1  - 2024 Jan 1;109(1):72-83
AB  - Treatment options for relapsed and refractory acute myeloid leukemia patients (R/R AML) are limited. This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) with or without venetoclax in patients with R/R AML. Thirty-seven and 81 patients received one course FLA-IDA with or without a 7-day course of venetoclax, respectively. The overall response rate (ORR) was significantly higher in FLAVIDA compared to FLA-IDA treated patients (78
LB  - PUB:(DE-HGF)16
C6  - pmid:37470150
DO  - DOI:10.3324/haematol.2023.282912
UR  - https://inrepo02.dkfz.de/record/277758
ER  -